Saliva Collection and Diagnostics Market Enhance non-invasive diagnostics with rapid, home-use testing solutions

Saliva Collection and Diagnostics Market Size and Forecast 2025 to 2034

The global saliva collection and diagnostics market size was calculated at USD 819.67 million in 2024 and is predicted to reach around USD 1,305.24 million by 2034, expanding at a CAGR of 4.76% from 2025 to 2034. Increasing demand for quick diagnoses of diseases is the key factor driving the growth of the saliva collection and diagnostics market. Also, rising public awareness regarding safe diagnostic solutions coupled with the innovations in infant sample collection technology, can fuel market growth further.

Saliva Collection and Diagnostics Market Key Takeaways

• The global saliva collection and diagnostics market was valued at USD 819.67 million in 2024.
• It is projected to reach USD 1,305.24 million by 2034.
• The saliva collection and diagnostics market is expected to grow at a CAGR of 4.76% from 2025 to 2034.
• North America dominated the global market with the largest market share of 44% in 2024.
• Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period.
• By site of collection, the submandibular/sublingual gland collection segment captured the biggest market share of 50% in 2024.
• By site of collection, the parotid gland collection segment is anticipated to grow at the fastest CAGR in the forecast period.
• By application, the disease diagnostics segment generated the major market share of 91% in 2024.
• By application, the forensic segment is expected to show the fastest growth in the forecast period.
• By end use, the diagnostic laboratories segment has held the largest market share of 80% in 2024.
• By end use, the pharmaceutical and biotechnology companies segment is expected to grow significantly during the forecast period.

Role of AI in the Saliva Collection and Diagnostics Market

Artificial intelligence (AI) can play a substantial role in the saliva collection and diagnostics market by enhancing the efficiency, precision, and duration of disease diagnosis and monitoring. It can use diagnostic images and clinical data to help diagnose oral conditions such as oral cancer, dental caries, and periodontal disease. Furthermore, AI can optimize the ability of salivary biomarkers to manage and diagnose maxillofacial diseases.

• In July 2024, OVUL announced the launch of its saliva-based AI fertility tracker. A groundbreaking tool created to help women accurately monitor their ovulation cycles with ease and accuracy.  This cutting-edge device combines the simplicity of a three-step process with advanced AI technology, turning daily health tracking into a quick and enjoyable moment.

U.S. Saliva Collection and Diagnostics Market Size and Growth 2025 to 2034

The U.S. saliva collection and diagnostics market size was evaluated at USD 252.46 million in 2024 and is projected to be worth around USD 404.89 million by 2034, growing at a CAGR of 4.84% from 2025 to 2034.

North America dominated the saliva collection and diagnostics market in 2024. The dominance of the region can be attributed to the increasing preference for saliva-based tests and the rise in cases of infectious diseases across the globe. Furthermore, in the region, the U.S. led the market owing to the growing demand for non-invasive testing methods offered by saliva sampling methods. Also, the strong presence of a healthcare infrastructure is supporting market expansion further.

• In August 2024, Mark Microbiotech announced the launch of a saliva-based organ age test. This epigenetics-based test marks the growth of the company’s business into a saliva-based genetic tests business.

Asia Pacific is anticipated to grow at the fastest rate in the saliva collection and diagnostics market during the forecast period. The growth of the segment can be linked to the rising incidence of infectious diseases where these tests are necessary. Moreover, saliva testing has gained huge acceptance because of its ease of collection and non-invasive nature. In the region, China is projected to show the fastest growth due to clear guidelines established by regulatory authorities.

Market Overview

The saliva collection and diagnostics market encompasses the collection, analysis, and interpretation of saliva samples for health care and research purposes. It also involves the use of saliva for biomedical research, diagnosing diseases, and non-invasive drug testing. Saliva is an important source of bodily information because it contains biomarkers like DNA and proteins that can help detect the presence of certain diseases like specific cancers and cardiovascular diseases. Also, saliva can show the body's physiological state, including endocrinal, nutritional, emotional, and metabolic variations.

Mouth and oral cancer rates in 2022

Saliva Collection and Diagnostics Market Growth Factors

• The rising prevalence of infectious diseases is expected to fuel saliva collection and diagnostics market growth shortly.
• Increasing the utilization of non-invasive saliva testing can boost market growth further.
• Ongoing innovations in non-invasive testing technologies will likely propel the saliva collection and diagnostics market growth soon.

Market Scope

Market Dynamics

Driver

Cost-effective collection and diagnostic offering

Collecting saliva DNA is not that expensive compared to other kinds of testing, such as blood and urine tests. Saliva samples do not need specific transportation and storage facilities from collection to processing. However, the blood samples need freezers, dry ice, and overnight shipping, while samples of saliva can easily be stored at the current temperature and transported via conventional methods, which makes the whole saliva collection process cheap.

• In November 2022, Quest Diagnostics announced the completion of its previously announced acquisition of select assets of LabCare Plus, the outreach laboratory services business of Summa Health, a big integrated healthcare organization.

Restraint

Complex sample treatment

Saliva is a high blend of many substances such as proteins, enzymes, nucleic acids, and other hormones. The complexity of this mixture can make it difficult to characterize and isolate salivary EVs, which sometimes can show different detection results. Moreover, there are many hurdles in reliably supplying the required materials for saliva collection and diagnostics.

Opportunity

Advancements in saliva-based POCT devices

The requirement for the advancement of saliva-based POCT devices is because of the ability of saliva the rapidly detect systemic and oral diseases like cancers, fungal and bacterial infections, and genetic disorders. Furthermore, the growing R&D in disease prediction by testing providers offers numerous opportunities for key players to enter the global saliva collection and diagnostics market.

• In November 2023, PCL, a Kosdaq-listed in vitro diagnostic medical device company, declared that its AI-based point of care testing (POCT) device, Pclok II Prep Universal, distinguished by the ability to diagnose various cancers, viruses, chronic diseases, and infectious diseases, has received U.S. FDA clearance.

Site of Collection Insights

The submandibular/sublingual gland collection segment dominated the saliva collection and diagnostics market in 2024. The dominance of the segment can be attributed to the increasing cases of sialolithiasis across the globe due to poor dieting habits along with the side effects of certain medications. Additionally, this disease is most prevalent among middle-aged adults. Also, the family history of stone diseases can raise the potential risks of these diseases, contributing to segment growth further.

• In August 2024, Lord’s Mark Microbiotech announced the launch of a saliva-based organ age test. This test, based on epigenetics, will assess the biological age of a patient's organs compared to their chronological age, offering insights for health interventions.

The parotid gland collection segment is anticipated to grow at the fastest rate in the saliva collection and diagnostics market over the forecast period. The growth of the segment can be linked to the growing incidence of rare salivary gland cancer, which often shows symptoms such as a noticeable lump or unease swallowing. Diagnosis of this disorder mostly relies on biopsies and imaging tests, including (PET) scans, CT scans, and MRIs.

Application Insights

The disease diagnostics segment dominated the saliva collection and diagnostics market. The dominance of the segment can be linked to the advancements in saliva diagnostic technology which makes it easier for the early detection of chronic diseases such as cancer and cardiovascular disease. Moreover, this method of testing is beneficial for diagnosing an extensive range of rare disease conditions like hormonal imbalances and certain infections.

The forensic segment is expected to show the fastest growth in the saliva collection and diagnostics market over the projected period. The growth of the segment can be driven by increasing innovations in DNA analysis coupled with the non-invasive nature of the sampling process. Saliva possesses proteins, DNA, and biomarkers that can give crucial data in forensic investigations like toxicology testing and individual identification. Furthermore, the raised demand for precise, rapid, and less invasive methods in forensic science has boosted the utilization of saliva-based diagnostics.

End-Use Insights

The diagnostic laboratories segment held the largest share of the saliva collection and diagnostics market in 2024. The dominance of the segment can be credited to the rising demand for diagnostic laboratories from customers across the globe. In addition, diagnostic laboratories use advanced analytical methods for the early detection of diseases and customized treatment for each patient. Diagnostic labs utilize automation and digitalization to test more samples in much less time.

• In November 2022, Quest Diagnostics announced that it had completed its previously declared acquisition of select assets of LabCare Plus, the outreach laboratory services business of Summa Health, an extensive integrated healthcare organization.

The pharmaceutical & biotechnology companies segment is estimated to grow at the fastest rate in the saliva collection and diagnostics market over the projected period. The growth of the segment is due to the ongoing partnerships and number of product launches by key market players. Partnerships between commercial enterprises and research organizations also propel innovation, leading to further segment expansion. Also, the biotechnology segment is anticipated to grow because of surging biotech product pipelines.

Saliva Collection and Diagnostics Market Companies

• Thermo Fisher Scientific, Inc.
• Neogen Corporation
• Abbott
• Sarstedt AG & Co.KG
• Autogen, Inc.
• Oasis Diagnostics
• Porex
• Salimetrics, LLC
• Takara Bio, Inc.
• Arcis Bio
• Orasure Technologies

Latest Announcements by Market Leaders

• In September 2024, Thermo Fisher Scientific announced the expansion of its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden, that will serve pharmaceutical and biotech customers with cutting-edge laboratory services.
• In October 2024, Neogen Corporation, an innovative leader in food safety solutions, announced that it had appointed Thierry Bernard as a director to its Board, effective November 1, 2024.

Segments Covered in the Report

By Site of Collection

• Parotid Gland Collection
• Submandibular/Sublingual Gland Collection
• Others

By Application

• Disease Diagnostics
• Forensic Applications
• Research

By End-Use

• Dentistry
• Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Research Institutes

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa